James S Blachly, MD
James S Blachly, MD
Assistant Professor of Internal Medicine, The Ohio State University
Verified email at
Cited by
Cited by
Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL
JA Woyach, AS Ruppert, NA Heerema, W Zhao, AM Booth, W Ding, ...
New England Journal of Medicine 379 (26), 2517-2528, 2018
BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia
JA Woyach, AS Ruppert, D Guinn, A Lehman, JS Blachly, A Lozanski, ...
Journal of Clinical Oncology 35 (13), 1437, 2017
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
MR Grever, O Abdel-Wahab, LA Andritsos, V Banerji, J Barrientos, ...
Blood, The Journal of the American Society of Hematology 129 (5), 553-560, 2017
Expression and prognostic impact of lncRNAs in acute myeloid leukemia
R Garzon, S Volinia, D Papaioannou, D Nicolet, J Kohlschmidt, PS Yan, ...
Proceedings of the National Academy of Sciences 111 (52), 18679-18684, 2014
BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor
HG Ozer, D El-Gamal, B Powell, ZA Hing, JS Blachly, B Harrington, ...
Cancer discovery 8 (4), 458-477, 2018
Targeting PI 3‐kinase (PI 3 K), AKT and m TOR axis in lymphoma
JS Blachly, RA Baiocchi
British journal of haematology 167 (1), 19-32, 2014
Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies
AK Eisfeld, J Kohlschmidt, K Mrózek, JS Blachly, CJ Walker, D Nicolet, ...
Leukemia 32 (6), 1338-1348, 2018
Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations
J Woyach, Y Huang, K Rogers, SA Bhat, MR Grever, A Lozanski, ...
Blood 134, 504, 2019
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia
AK Eisfeld, K Mrózek, J Kohlschmidt, D Nicolet, S Orwick, CJ Walker, ...
Leukemia 31 (10), 2211-2218, 2017
Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged< 60 years
AK Eisfeld, J Kohlschmidt, A Mims, D Nicolet, CJ Walker, JS Blachly, ...
Leukemia 34 (12), 3215-3227, 2020
Emerging drug profile: cyclin-dependent kinase inhibitors
JS Blachly, JC Byrd
Leukemia & lymphoma 54 (10), 2133-2143, 2013
Acalabrutinib plus obinutuzumab in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia
JA Woyach, JS Blachly, KA Rogers, SA Bhat, M Jianfar, G Lozanski, ...
Cancer discovery 10 (3), 394-405, 2020
Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A
M Bill, K Mrózek, J Kohlschmidt, AK Eisfeld, CJ Walker, D Nicolet, ...
Proceedings of the National Academy of Sciences 117 (42), 26340-26346, 2020
Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically
K Mrózek, AK Eisfeld, J Kohlschmidt, AJ Carroll, CJ Walker, D Nicolet, ...
Leukemia 33 (7), 1620-1634, 2019
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia
E Young, D Noerenberg, L Mansouri, V Ljungström, M Frick, LA Sutton, ...
Leukemia 31 (7), 1547-1554, 2017
Quality control for RNA-Seq (QuaCRS): an integrated quality control pipeline
KW Kroll, NE Mokaram, AR Pelletier, DE Frankhouser, MS Westphal, ...
Cancer informatics 13, CIN. S14022, 2014
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia
B Bhatnagar, AK Eisfeld, D Nicolet, K Mrózek, JS Blachly, S Orwick, ...
British journal of haematology 175 (2), 226-236, 2016
HDAC inhibition induces microRNA-182, which targets RAD51 and impairs HR repair to sensitize cells to sapacitabine in acute myelogenous leukemia
TH Lai, B Ewald, A Zecevic, C Liu, M Sulda, D Papaioannou, R Garzon, ...
Clinical cancer research 22 (14), 3537-3549, 2016
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia
KA Rogers, LA Andritsos, L Wei, EM McLaughlin, AS Ruppert, ...
Blood, The Journal of the American Society of Hematology 137 (25), 3473-3483, 2021
PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL
D El-Gamal, K Williams, TD LaFollette, M Cannon, JS Blachly, Y Zhong, ...
Blood, The Journal of the American Society of Hematology 124 (9), 1481-1491, 2014
The system can't perform the operation now. Try again later.
Articles 1–20